iRhythm Technologies Inc. (IRTC) saw its shares plummet 5.11% during intraday trading on Friday, as the stock faced selling pressure following a series of analyst price target reductions.

Despite reporting strong quarterly earnings that significantly beat estimates, with adjusted EPS of $0.29 versus the $0.03 consensus expectation and revenue of $208.89 million exceeding the $201.59 million forecast, multiple Wall Street firms have recently lowered their price targets on the healthcare technology company.

JP Morgan reduced its target to $215 from $240, Canaccord lowered its target to $198 from $212, and Truist Securities adjusted its price target to $200 from $215, though all three firms maintained their Buy ratings on the stock. These downward revisions in price targets appear to be weighing on investor sentiment despite the company's solid financial performance.